This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Kadmon Holdings, Inc.

Drug Names(s): XL844

Description: XL844 is an orally available, potent inhibitor of Chk 1 and 2, two proteinkinases that facilitate DNA repair after exposure to DNA-damaging agents(e.g., chemotherapy). Chk inhibition blocks the ability of cells to detect andrepair DNA damage, and in tumor models leads to increased efficiency ofchemotherapeutic agents and radiation.

Deal Structure: GlaxoSmithKline and Exelixis have a partnership focused on the collaboration in 12 programs (XL784, XL647, XL999, XL880, XL184, XL820, XL844, XL281, XL418, XL228 and two earlier stage oncology programs). GlaxoSmithKline has the right to select from these programs up to two compounds at proof-of-concept (completion of Phase IIa clinical trial) or three compounds if GlaxoSmithKline extends the collaboration.

In June 2008, Exelixis announced that the company and GlaxoSmithKline will bring their collaboration to a conclusion on October 27, 2008.

In October 2008, Exelixis announced that GlaxoSmithKline decided not to exercise its option to license XL184, XL281, XL228, XL820, and XL844.

Sometime in Q4 2014, Kadmon licensed XL844 from Exelixis.

Partners: Exelixis, Inc.

XL844 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug